Although SAMSN1 sometimes expressed in nucleus (8.3% of all glioma cases, 4.3% in GBM), high nuclear expression was very rare, only 0.7% of all glioma cases, compared with 60.1% glioma with a high cytoplasmic expression of SAMSN1. This evidence concerns the gene SAMSN1 and central nervous system cancer.